John Hetherington

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 2K citations · Full text

Medicine, Oncology, Urology +17

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

Padraig Warde, Malcolm Mason, Keyue Ding et al. · The Lancet · 2011 · 580 citations

Medicine, Oncology, Urology +16

Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial

Reza Adib, John Anderson, M Handley Ashken et al. · Kent Academic Repository (University of Kent) · 1997 · 552 citations

Medicine, Oncology, Urology +17

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

Nicholas D. James, Melissa Spears, Noel W. Clarke et al. · European Urology · 2014 · 436 citations · Full text

Medicine, Biostatistics, Oncology +17

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

Malcolm D. Mason, Wendy R. Parulekar, Matthew R. Sydes et al. · Journal of Clinical Oncology · 2015 · 259 citations · Full text

Medicine, Oncology, Radiation Oncology +14